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Abstract
Background: Common genetic polymorphisms at chromosome 4q25 were associated with increased 
susceptibility to atrial fibrillation (AF). However, it remained controversial whether these variants could 
be used as risk predictors for AF recurrence after catheter ablation. We therefore performed a meta-
analysis to quantify the association between rs2200733 C>T/rs10033464 G>T and AF recurrence.
Methods: Relevant studies were systematically retrieved from PubMed, Web of Science, Elsevier data-
base and Cochrane library through November 2016. Data were abstracted and pooled using Stata 12.0 
software.
Results: A total of 2,145 patients undergoing catheter ablation were included. Patients with rs2200733 
TT or TT+CT showed an overall increased susceptibility to AF recurrence (homozygous model [TT 
vs. CC]: odds ratio [OR] = 2.03, 95% confidence interval [CI] 1.49–2.76, p = 0.000; dominant model 
[TT+TC vs. CC]: OR = 1.48, 95% CI 1.17–1.87, p = 0.001; recessive model [TT vs. TC+CC]:  
OR = 1.88, 95% CI 1.12–3.15, p = 0.017). Subgroup analysis also identified a positive relation in 
Caucasians and late recurrence of AF in allelic, homozygous and dominant comparison. Moreover,  
a significant increased risk of AF recurrence was observed in patients with rs10033464 TG or TT+TG 
(heterozygous model [TG vs. GG]: OR = 1.46, 95% CI 1.01–2.12, p = 0.047; dominant model 
[TT+TG vs. GG]: OR = 1.51, 95% CI 1.04–2.17, p = 0.029).
Conclusions: After catheter ablation, rs2200733 (TT or TT+TC) and rs10033464 (TT+TG or TG) 
were associated with increased risk of AF recurrence. (Cardiol J 2018; 25, 5: 628–638)
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Introduction
Atrial fibrillation (AF) is one of the most 
prevalent forms of cardiac dysrhythmia in clinical 
practice, which affects 33.5 million individuals glob-
ally [1]. Several factors already have been identified 
to increase the susceptibility to AF, such as smok-
ing, sex, and obesity [2–4]. Interestingly, genetic 
predisposition has been added into the long list of 
risk factors for AF. Gudbjartsson et al. [5] found 
common genetic polymorphisms at chromosome 
4q25 (PITX2) locus, including rs2200733 C>T 
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(at-risk allele T) and rs10033464 G>T (at-risk 
allele T), were associated with increased suscepti-
bility to AF [5]. The association between rs2200733 
and AF was further replicated in Indian [6], Spanish 
[7], Danish [8], Italian [9] and Polish [10] as well 
as Chinese populations [11]. Three different geno-
types, CC, CT and TT were identified in rs2200733 
with minor allele frequency 0.21 to 0.39 across 
different ethnic groups [12, 13]. The prevalence 
of rs10033464 G>T was reported from 19% to 
32% predisposed to AF recurrence after ablation 
[14, 15]. Several genetic models, including allelic 
(T vs. C for rs2200733, T vs. G for rs10033464), 
heterozygous (TC vs. CC for rs2200733, TG vs. 
GG for rs10033464), homozygous (TT vs. CC for 
rs2200733, TT vs. GG for rs10033464), domi-
nant (TT+TC vs. CC for rs2200733, TT+TG vs. 
GG for rs10033464), recessive (TT vs. TC+CC 
for rs2200733, TT vs. TG+GG for rs10033464) 
models were applied to quantify the association 
between rs2200733/rs10033464 and AF recurrence 
after ablation [10, 15, 16].
However, the relationship between two 
common polymorphisms (rs2200733 C>T and 
rs10033464 G>T) at chromosome 4q25 locus and 
AF recurrence after catheter ablation remained 
controversial. Husser et al. [15] provided evidence 
that the presence of any variant allele (rs2200733 T 
or rs10033464 T) increased the risk of AF recur-
rence within the first 7 days and between 3 and 
6 months in Caucasian patients of German descent. 
And both variants independently predicted AF 
recurrence when evaluated by dominant models 
in multivariable analysis [15]. In Chinese Han 
population, single nucleotide polymorphism (SNP) 
rs2200733 was an independent factor for AF recur-
rence after ablation, and the risk allele T was as-
sociated with AF recurrence [17]. Zhao et al. [16] 
also reported rs2200733 TT was able to predict 
a 1.8-fold increased risk for clinical recurrence 
after catheter ablation. On the contrary, Kiliszek 
et al. [18] found that rs2200733 C>T or rs10033464 
G>T failed to correlate with AF recurrence after 
a single AF ablation in long-term follow-up (me- 
dian of 45 months). In Korean patients, rs2200733 T 
allele was strongly associated with AF, but this 
SNP again failed to predict clinical recurrence af-
ter catheter ablation [12]. Therefore, the present 
study performed a meta-analysis to investigate 
the effect of common non-coding variants on chro-
mosome 4q25 (rs2200733 C>T and rs10033464 
G>T) on the risk of AF recurrence after catheter 
ablation.
Methods
Literature search
A systematic search of PubMed, Web of Sci-
ence, Elsevier database and Cochrane library was 
undertaken for studies through November 2016. 
The search terms included all possible combina-
tions “rs2200733”, “rs10033464”, “SNP”, “poly-
morphism or variant”, “atrial fibrillation”, “AF”, 
“4q25 (PITX2)”, “ablation”, “outcome”, and “AF 
recurrence after ablation”. Manual searches of 
study references were also conducted. Moreover, 
several related articles from reviews and other 
pertinent sources such as research bibliographies 
were inspected as well. 
Inclusion and exclusion criteria
An initial screening for titles and abstracts 
was performed. A second screening was based on 
full-text review. The following criteria were used 
to evaluate whether a study was eligible: 
a) The association between rs2200733/rs10033 
464 and AF recurrence after ablation must be 
assessable. 
b) The genotype data of  rs2200733 and 
rs10033464 must be provided. 
c) The study has a cohort design or has a case-
control. 
d) The research should report an estimate of 
risk for AF recurrence after ablation with 
a corresponding 95% confidence interval (CI). 
e) If the same population was studied in more than 
one study, study with larger sample size and 
more comprehensive outcome were included. 
f) AF recurrence was defined according to 
the Heart Rhythm Society/European Heart 
Rhythm Association/European Cardiac Ar-
rhythmia Society Consensus Statement rec-
ommendations. Late recurrence of AF (LRAF) 
was defined as any episode of atrial tachyar-
rhythmia, including atrial tachycardia, atrial 
flutter, or AF (AT/AF) lasting more than 30 s 
that occurred after a 3-month post-ablation 
blanking period. Early recurrence of AF 
(ERAF) was defined as an AF episode within 
3 months post-ablation blanking period. 
Studies were excluded if they met the follow-
ing criteria: 
a) It is a review, letter, conference abstracts, and/ 
/or case report. 
b) The study lacked information on the risk of 
AF recurrence after ablation. 
c) The study did not provide sufficient data. 
630 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 5
Data extraction and quality assessment
An outcome of interest in this study was the 
capability of rs2200733 and rs10033464 to predict 
the risk of AF recurrence after catheter ablation. 
After careful review, data was extracted using 
a standardized data-collection form for each eligi-
ble article: first author’s name, publication year, 
ethnicity/nationality, patient number, patient char-
acteristics. Clinical end point, quality assessment, 
comorbid conditions, anatomic factors, ablation 
strategies, methods of AF recurrence ascertain-
ment, and adjunctive post-operation therapy were 
also considered. The quality of each study was 
evaluated according to the Newcastle-Ottawa qual-
ity assessment scale (NOS) [19].
Statistical analyses
All statistical analyses were performed with 
Stata 12.0 software (StataCorp, College Station, 
TX, USA). Odds ratio (OR) was used as a common 
measure of the association between rs2200733 
C>T/ rs10033464 G>T and AF recurrence. Pooled 
ORs were performed for allelic comparison (T vs. 
C for rs2200733, T vs. G for rs10033464), het-
erozygote model (TC vs. CC for rs2200733, TG 
vs. GG for rs10033464), homozygote model (TT 
vs. CC for rs2200733, TT vs. GG for rs10033464), 
dominant model (TT+CT vs. CC for rs2200733, 
TT+GT vs. GG for rs10033464), recessive model 
(TT vs. TC+CC for rs2200733, TT vs. TG+GG 
for rs10033464), respectively. Cochran’s Q test and 
I2 statistic were used to evaluate the consistency 
across studies. Fixed effect model was used when 
p < 0.10 and I2 < 50%; otherwise random effect 
model was used. Sensitivity analysis was performed 
through omitting individual study one-by-one to 
investigate the influence of single study on the 
overall risk estimates. Subgroup analysis was also 
performed where appropriate. Potential publication 
bias was checked by Begg’s funnel plots and Egger’s 
regression test. An asymmetric plot and p value of 
the Egger test less than 0.05 was considered a sig-
nificant publication bias. Unless otherwise stated, 
p < 0.05 was considered statistically significant.
Results
Study characteristics
A total of 32 records were identified through 
the above mentioned literature search strategy. 
After screening titles and abstracts in the first 
round, 12 articles were excluded. Following this, 
the remaining 20 articles, 7 articles were excluded 
that did not involve AF recurrence, rs2200733 or 
rs10033464. After reviewing full texts and data, 
8 articles were excluded (5 articles without sufficient 
information on risk estimate, and 3 articles without 
ablation). Finally, 5 articles were eligible for inclu-
sion in this study. Husser et al. [15] reported ORs 
for both ERAF and LRAF; each OR was included in 
this analysis. A total of 2,145 patients who under-
went catheter ablation were included. The charac-
teristics of the included studies were presented in 
Table 1 and Table 2. The NOS scores of included 
studies were all more than 7 scores (high quality).
In general, AF ablation strategy was comparable 
among included studies. A 3-dimensional mapping 
system was used for catheter orientation, computed 
tomographic image integration, and tagging of the 
ablation sites (NavX /NavX-Ensite system [12, 15]; 
or CARTO system [16, 17]; or LocaLisa system [18]). 
Transseptal access was performed. And an irrigated-
tip ablation catheter was used in 4 studies [12, 15–17]. 
A non-irrigated catheter was used in 1 study [18] 
under the consideration of non-significant difference 
in AF recurrence between patients treated with 
irrigated and non-irrigated catheters [20]. Circum-
ferential pulmonary vein isolation with bidirectional 
block was a major ablation endpoint at all centers. 
Additional ablation to the left atrial (LA) roof, basal 
posterior wall, posterior inferior wall, and anterior 
wall, mitral isthmus, cavotricuspid isthmus, superior 
vena cava, non-pulmonary vein (PV) foci, complex 
fractionated atrial electrograms were performed 
based on operator discretion.
Genotypic association between rs2200733 
C>T and AF recurrence 
In the primary analysis, the associations be-
tween rs2200733 C>T and AF recurrence after 
ablation were analyzed under five genetic models 
(Table 3). Fixed-effects model was used in the 
heterozygous, homozygous and dominant model. 
Random-effects model was used in the allelic and 
recessive model as a result of heterogeneity. Over-
all, significant positive relation was observed in 
four genetic models (T vs. C: OR = 1.50, 95% CI 
1.18–1.90, p = 0.001; TT vs. CC: OR = 2.03, 95% CI 
1.49–2.76, p = 0.000; TT+CT vs. CC: OR = 1.48, 
95% CI 1.17–1.87, p = 0.001; TT vs. TC+CC: 
OR = 1.88, 95% CI 1.12–3.15, p = 0.017; Fig. 1). 
No significant association was found in heterozy-
gous comparison (TC vs. CC: OR = 1.24, 95% CI 
0.96–1.59, p = 0.096), but a trend of increased 
susceptibility still existed.
Subgroup analysis was conducted according 
to ethnicity and time to AF recurrence (Table 3). 
In Caucasians, a significant association was 
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observed in three genetic models except for the 
heterozygous model (TC vs. CC: OR = 1.31, 95% 
CI 0.91–1.89, p = 0.141) and recessive model (TT 
vs. TC+CC: OR = 1.79, 95% CI 0.87–3.70, p = 
= 0.116). A significant association was observed for 
LRAF in four genetic models except for heterozy-
gous comparison (TC vs. CC: OR = 1.15, 95% CI 
0.84–1.58, p = 0.382). No association was found 
to be significant in any genetic models for ERAF. 
Genotypic association between rs10033464 
G>T and AF recurrence 
In the secondary analysis, the associations 
between rs10033464 G>T and the risk of AF re-
currence were evaluated. A significant increased 
risk of AF recurrence was identified in the allelic 
model (T vs. G: OR = 1.44, 95% CI 1.04–2.00, 
p = 0.027), heterozygous model (TG vs. GG: 
OR = 1.46, 95% CI 1.01–2.12, p = 0.047) and 
dominant model (TT+TG vs. GG: OR = 1.51, 
95% CI 1.04–2.17, p = 0.029, Table 4, Fig. 2). 
And a non-significant association was observed in 
homozygous comparison (TT vs. GG) or recessive 
comparison (TT vs. TG+GG). However, this result 
should be interpreted with caution due to a limited 
number of studies.
Sensitivity analysis and publication bias
Sensitivity analysis was performed to evalu-
ate the influence of single study on the pooled 
ORs for rs2200733 C>T and rs10033464 G>T by 
deleting each study once in every genetic model. 
Consistently, the pooled estimate remained non-
significant. No publication bias for the association 
between rs2200733 C>T and AF susceptibility 
was identified by Begg’s funnel plot (p = 0.133; 
Table 3) or Egger’s regression test (p = 0.075; 
Table 3). Symmetrical funnel plots were obtained 
in all five genetic models. Due to limited studies, 
no funnel plot or Egger tests were performed for 
the association between rs10033464 G>T and the 
risk of AF recurrence after ablation. 
Discussion
Catheter ablation has been employed as 
a first-line treatment for rhythm control in many 
patients with AF, especially in whom failed in 
anti-arrhythmic drug treatment [21]. Although 
ablation is effective [22], large effective variances 
ranging from 29% to 90% in ablation outcome are 
observed in real clinical setting [21, 23]. Winkle 
et al. [24] established a clinical scoring system to 
predict long-term freedom from AF after ablation. 
Genome-wide association studies identified several 
AF-susceptibility loci, such as rs2200733 C>T 
and rs10033464 G>T at chromosome 4q25, could 
be used as prognostic factors. And recent studies 
have focused on their potential to predict AF risk 
in patients undergoing ablation.
In this meta-analysis, carriers of at least 1 risk 
allele conferred an increased risk of 48% or 51% 
for AF recurrence when evaluated by dominant 
model for rs2200733 or rs10033464, respectively. 
However, the mechanisms underlying these as-
sociations remained elusive. These noncoding 
Figure 1. Forest plot of dominant model of rs2200733 for overall comparison (TT+CT vs. CC); LRAF — late recurrence 
of atrial fibrillation; ERAF — early recurrence of atrial fibrillation. CI — confidence interval; OR — odds ratio.
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variants existed in close proximity (~150 kb) to 
the cis-regulatory region of paired-like homeodo-
main transcription factor 2 (PITX2), and modu-
lated PITX2 activity through transcription level 
as postulated [25, 26]. PITX2 efficiently regulated 
atrial resting membrane potential and involved in 
the formation, differentiation and proliferation of 
pulmonary myocardium [27, 28]. Three isoforms 
of PITX2 (PITX2a, PITX2b, and PITX2c) have 
been identified, among which PITX2c was the 
only isoform expressed in the left atrium [29]. 
PITX2c directs formation of left and right anatomic 
characteristics and mediates left-right asymmetry 
signaling cascade [28, 30]. It also efficiently modu-
lates ion channels and calcium handling proteins in 
atrial cardiomyocytes [28, 31, 32]. Down-regulation 
or up-regulation of PITX2c is associated with AF 
arrhythmogenesis [31, 32]. In human patients with 
sustained AF, PITX2c insufficiency could lead to 
atrial electrical and structural remodeling [10, 17, 
33]. Taking these findings together, we speculated 
that rs2200733 or rs10033464 could modulate 
the expression of PITX2c. And PITX2c-mediated 
alterations in PV phenotype (such as arrhythmo-
genicity of PV myocardium, PV myocardial sleeve 
or LA/PV electrophysiology) affected response to 
PV isolation (PVI). However, PVI itself might be 
different between the centers: size of isolation area 
around PV, durability of PVI lesion or the usage 
of the contact force sensing ablation catheter etc. 
Thus further prospective researches, especially 
large-scale multicenter trials with standardized 
clinical procedures, are required to solve these 
issues. 
In accordance with the finding of Husser et 
al. [15], a significant increased risk of LRAF was 
identified in rs10033464 in allelic, heterozygous 
and dominant comparison, but such association 
needs to be further validated as a result of limited 
studies. We also observed a robust genotypic as-
sociation between rs2200733 and LRAF in allelic 
model, homozygous model, dominant model and 
recessive genetic model, which were consistent 
with precious reports of Husser et al. [15], Zhao et 
al. [16], Chen et al. [17] and Benjamin Shoemaker 
et al. [34]. But no association was found to be 
significant in any genetic models for ERAF. Choi 
et al. [12] reported lack of association between 
rs2200733 and LRAF. Kiliszek et al. [18] found 
rs2200733 C>T or rs10033464 G>T failed to 
correlate with AF recurrence in a median of 45 
months follow-up. Many potential causes could 
underlie the discordant results. The incidences 
of recurrence in the entire follow-up period were Ta
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Figure 2. Forest plot of dominant model of rs10033464 for overall comparison (TT+GT vs. GG); LRAF — late recur-
rence of atrial fibrillation; ERAF — early recurrence of atrial fibrillation. CI — confidence interval; OR — odds ratio.
not provided in Choi’s and Kiliszek’s studies, 
thus data for ERAF in Korean and 6-month AF 
recurrence in Polish were used in the current 
meta-analysis. It is possible that the influence 
of genetic factors might have different impart on 
AF recurrence depending on post-ablation period 
(occurring within 3-months or later than 3-months 
after ablation). Other potential causes, such as 
the variability of technical approach to ablation 
procedure, ability for AF surveillance, frequency 
of polymorphism among studied populations, com-
position of AF patients and sample size, as well 
as the adjusted covariates, would be confounders 
in AF recurrence.
Conclusions
Common 4q25 genetic variants rs2200733 (TT 
or TT+TC) and rs10033464 (TT+TG or TG) are 
associated with increased risk of AF recurrence. 
And rs2200733 C>T can be used as a clinical 
marker for outcome prediction before embark-
ing on the procedure. Further prospective stud-
ies, especially large-scale multicenter trials with 
standardized clinical procedures, are warranted 
to ascertain the mechanistic relationship between 
rs2200733/ rs10033464 and clinical response after 
ablation. These studies will eventually contribute 
to establishing the genotype-based algorithm for 
prediction and developing the genotype-guided 
therapy in clinical practice.
Limitations of the study
Under review was the effect of rs2200733 
and rs10033464 on the risk of AF recurrence after 
catheter ablation, but the following limitations are 
still worth mentioning. First, this is a retrospec-
tive observational study that needs prospective 
confirmation. Unavoidable differences and some 
variability introduced by operators exist between 
centers, which may diminish the strength of ob-
served associations or contribute to the lack of an 
association in heterozygous comparison or reces-
sive comparison in subgroup analysis. Second, it 
is possible that variability and accuracy together 
with the intensity of AF monitoring after ablation 
inherently limited the interpretation of data in 
the current study. Asymptomatic AF after abla-
tion was not investigated in all centers. Third, 
the presence of 1 variant indicated an increased 
risk for AF recurrence, but variant carriers vary 
greatly in different centers and represent only 
a minority of the AF population. Thus, prospective 
studies, especially large-scale multicenter trials 
with standardized clinical procedures are warranted 
to fully appreciate their risk. Fourth, although it 
was speculated that these variants modulate the 
expression of PITX2c and result in alterations in 
PV phenotype, PV-LA reconduction is still the 
prevailing cause for AF recurrence after ablation. 
Other mechanisms such as progression of low volt-
age area in LA, non-PV foci also may be associated 
with AF recidivism. However, because whether 
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re-ablations were performed or not has remained 
unknown during the follow-up period in these 
centers, reconduction could not be assessed. AF 
recurrences might be due to different mechanisms 
that are not captured with the analyzed variants in 
these studies. And it is also worth noting that 4q25 
variants may simply be used as one of the clinical 
markers for outcome prediction. Finally, given 
the fact that PITX2 adjacent non-coding RNA and 
enhancer binding protein 2 alpha were involved in 
regulation of PITX2c expression [35, 36], it cannot 
be ruled out that rs2200733 or rs10033464 vari-
ants may also control the expression of coding or 
non-coding regions of other AF-associated genes 
or SNPs through gene-gene interaction [37]. Not 
all AF-susceptibility variants which were in linkage 
disequilibrium with these variants were included 
in this analysis. The impact of potential gene-gene 
interaction at 4q25 locus to the clinical response 
for ablation remained unknown.
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